BT
Bioxcel Therapeutics
BTAI13F as of Jun 30, 2026 · next update ~Nov 14
Limited coverage
Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.
Who's buying BTAI
Top funds mostly added to Bioxcel Therapeutics in Q2 (Apr–Jun)
Buying:
Funds1InsidersCongress
- Top funds1 of 1 bought more, 0 sold some. Largest: Oaktree Capital Management, $1.9M (0% of its portfolio).
- InsidersNo buys, 4 sales in 12 months.
- CongressNo trades disclosed in the last 12 months.
1 fund$1.9M held0.1% avg. weightQ2: 1 bought / 0 sold
13F reports are a snapshot as of Jun 30, 2026; funds may have traded since. Insiders often sell for personal reasons (taxes, diversification, planned sales).
Share price · market data, not from 13F reports
Q2 2026
Insider trades (Form 4)
Last 2 years · 9 filings